The 25th anniversary of the first breakthrough in our understanding of the Human Genome is fast approaching. It was on June 26 2000, at a solemn briefing at the White House, that the completion of the “working draft” of the Human Genome Project (HGP) was announced. The session, chaired by Bill Clinton, then president of the United States, and former British Prime Minister Tony Blair, was attended by the two leading researchers behind the HGP, Francis Collins and Craig Venter, who competed separately to acquire knowledge of the genetic information contained in our DNA.
The genome that scientists sought to decipher refers to the basic genetic information of the human species. The idea for the HGP began to take shape in 1984, at a science summit held in Alta (Utah, United States), where a large group of researchers agreed to launch a massive project to learn more about the molecular causes of the DNA alterations involved in many diseases, especially cancer, and facilitate the development of gene therapy or other biotechnological applications. The project was first proposed in 1986 at a meeting in the city of Santa Fe (California, United States) by Renato Dulbecco (1914-2013), winner of the 1975 Nobel Prize in Medicine [1], and was subsequently published in Science. By this time, sufficient knowledge had been attained to undertake the task. Scientists knew the structure of DNA (1953) and how the message of genes is translated by the universal genetic code (1964), and a series of techniques had just been developed that allowed stretches of several hundred DNA bases to be isolated, cut, cloned, and sequenced (1970s). Everything was set to decode the genetic message of our genome.
In 1990, an international organization called HUGO (Human Genome Organization) – the UN of the Human Genome – was established, which, on the initiative of US researchers, was joined by research groups from Great Britain, France, Germany, Japan, and China, who would distribute the task in a coordinated manner [1]. The HGP was approved by the Academy of Sciences, the National Institutes of Health, and the U.S. Government, and endorsed by Congress in 1988. After two years of preparations, work finally began.
The human genome to be sequenced has about 3.1 billion base pairs (megabases or Mb) and was thought to contain around 100,000 genes. The initial goals of the HGP were as follows: a) to decipher the entire message of the genome (structural genomics); b) to develop rapid and effective techniques for sequencing the entire genome; c) to identify gene variations (allelic variations); d) to reveal the functions of the genes and regions of the genome (functional genomics); e) to launch in parallel the analysis of the genome of other model organisms (yeast, nematode, Drosophila, mouse); f) to analyze the ethical, legal and social implications (ELSI) of genomics; g) to develop bioinformatics and computing tools for the use of gene and sequence data; h) to store the information on the genes and genomes that was being generated in open access databases; i) to train scientists for genome research and analysis; and j) to make all the information available to the private sector.
The first stage of the HGP was to complete a kind of working draft or skeleton of the genome and was planned for completion in late 2001. The second stage would attempt to complete the knowledge of the rest of the genome, filling in the remaining gaps and would have to be completed in 2020. However, thanks to good coordination and the development of increasingly effective methodologies, the work progressed rapidly. At the end of 1999, the journal Nature published the complete sequence of chromosome 22, the smallest in the genome (33 Mb), and on 8 May 2000, the same journal published the sequence of chromosome 21 (46.7 Mb), of considerable importance due to its involvement in Down syndrome. Just one month later, the working draft, involving all 24 chromosomes, was declared complete.
After that, the draft genome served as the basis for adding the missing details. On 23 April 2003, fifty years after the publication of the structure of the DNA double helix in Nature, an event of similar magnitude was repeated in the same journal. Both Nature and Science dedicated a special issue to describing the human genome. A consortium of laboratories, known as Telomere to Telomere, or the T2T Consortium, subsequently completed the work by filling in the most recalcitrant areas of the genome (centromeres, telomeres, and other regions). The HGP was completed in April 2023.
A significant event that undoubtedly influenced the rapid development of the HGP was the split of the researcher and entrepreneur Craig Venter (b. 1946) from the International Consortium led by Francis Collins. Venter created an independent working group to develop his own HGP using a different work strategy.
The initial project led by James Watson, Francis Collins and other researchers set out to sequence the DNA of the entire genome, the 24 chromosomes (22 autosomes + XY), from end to end. However, Craig Venter thought that it was more practical to prioritize the sequencing of the genes expressed in the differentiated cells where they are active; to this end, he considered it more beneficial to begin with the knowledge of the proteins specifically produced in each type of cell, using the intermediate products of their expression, the messenger RNAs (mRNAs). A number of biotechnology companies joined together to form the private consortium ‘Celera Genomics’ in order to finance and develop the work.
The strategy of the International Consortium was undoubtedly more complex, but it offered a complete version of the genome. It has emerged as the preferred model in the genome studies of the hundreds of species that have been conducted so far. For its application in the HGP, it was essential to spread the workload among different laboratories. Each region of the genome was cut into thousands of manageable fragments, which were then preserved as clones after being introduced into strains of microorganisms. This is how the so-called “genomic libraries” were created. From these libraries, the DNA of each fragment would be isolated and sequenced, and then the contiguous regions would be joined, as if it were a huge puzzle. Since the sequencing of the fragments was limited to stretches of a few hundred base pairs, extremely resourceful experimentation strategies had to be developed based on sequencing fragments with overlapping ends. To do this, each region to be studied gave rise to several libraries generated with different “molecular scissors” (restriction endonucleases), which recognized different “targets” in the same DNA segment. The location of each fragment would require powerful computer support to properly order the contiguous overlapping fragments.
Apart from the applications presented below, it should be noted that this great project has resulted in a stream of valuable contributions to Medicine and Biology. The organization of the HGP has served as a model for approaching other major research projects, such as the Cancer Genome Atlas, the 1000 Genomes Project, the ENCODE project (Encyclopedia of DNA Elements), the BRAIN project (the Brain Research Through Advancing Innovative Neurotechnologies Initiative), etc. This is a new way of conducting research based on the openness to cooperation between dozens of laboratories and thousands of researchers through international consortia.
Another aspect to highlight is the creation of databases on the thousands of genome projects that have been carried out since the launch of the HGP. The end result is the acquisition of knowledge of the genomes of many species of animals, plants and microorganisms, the details of which can be accessed in public databases, such as the following:
- GenBank, a large publicly accessible database maintained by the US National Institutes of Health (NIH). Also of proteins, bibliographic information (Medline) and genomes.
- TIGR Databases: These databases provide information on the first genomes that were sequenced and links to the analyses of each of them.
- EBI: European Bioinformatics Institute.
- The Wellcome Trust Sanger Institute, together with TIGR, the Trust was actively involved in the sequencing of many genomes.
- Ensembl, eukaryotic genomes.
- SGD, Saccharomyces Genome Database. Provides biological information for the genome of yeast, a model species of single-celled eukaryote.
- FlyDB, a database for the genome of Drosophila.
Advances in bioinformatics have made it possible to create programs that can find genes, open reading frames (ORFs) in the sea of DNA of each genome. They enable the position of the start and stop codons of the genes to be detected, in addition to locating the regions that are translated and those that are not (exons and introns, respectively). Likewise, DNA sequencing and gene detection make it possible to predict the amino acid sequence of the proteins they encode, thanks to the universality of the genetic code.
Finally, it should be noted that the cost of sequencing decreased drastically while the HGP was underway, and that the tools for analyzing genomes are much faster. A complete individual human genome can now be sequenced in a few hours for a few hundred Euros and, thanks to the use of artificial intelligence, the details of the genomes can be studied without needing to have great computer skills.
Applications of the HGP
The HGP has been the catalyst that has driven two types of applications of great importance, one basic and the other applied. In the biomedical context, it has led to the development of three types of applications: diagnostic, therapeutic and pharmacological; and in the context of biology, the study of the organization of genetic information and phylogenetic relationships of all species.
Understanding the genetic basis of many diseases has also enabled the development of laboratory tests that can diagnose these conditions before their onset. These tests are valid at any time during the life cycle, and are in fact used in embryos produced by in vitro fertilization (preimplantation genetic diagnosis), during the fetal stage (prenatal diagnosis) and in adults. Early diagnosis of a genetic disease may facilitate the adoption of treatments for the total or partial correction of the disease or any of its manifestations.
Additionally, knowing the DNA sequences of certain genes involved in hereditary disorders and diseases allows the development of gene therapy techniques. This refers to the restoration of the defective gene in an individual with an inherited disease, either by inserting a functional gene into the genome, or by silencing, modifying the expression level, or editing the gene sequences of the altered gene. Intense efforts are currently underway to develop corrective treatments that can be applied even in utero, during the pregnancy. At present there are more than 100 clinical trials that use CRISPR-Cas9 technology for diagnostic or therapeutic purposes registered in the Clinicaltrials.gov database.
Another highly important biomedical application is that of “pharmacogenomics”, which studies the most appropriate pharmacological treatments for the individual genomic profiles of patients with genetic diseases. According to the US Food and Drug Administration (FDA), “[p]harmacogenomics can play an important role in identifying responders and non-responders to medication, avoiding adverse events, and optimizing drug dose”.
Apart from Medicine, the data obtained from genome projects on multiple species have paved the way for “comparative genomics”, which compares the similarities and differences in the genomes of different species. This type of study is making it possible to analyze biodiversity, evolutionary origin and phylogenetic relationships between species. Determining the evolutionary connections between humans and other species is particularly interesting. Anthropogenetics has allowed us to comprehend the close relationship between man and his nearest extinct relatives, the Neanderthals and Denisovans.
Another basic aspect that arises from the understanding of the human genome and that of thousands of species relates to how genetics is viewed in terms of gene expression. This has long been complicated for us, and the simple “one gene-one protein” paradigm has been dismantled. Today we know more about how information from genes is used in determining various products, and how many phenotypic traits related to diseases or other characteristics of interest are modulated by the indirect effect of multiple genes, or by mutations that may be scattered throughout the genome. While each gene has its functional role, the image of a given phenotype has shifted to the idea that its expression is the result of an interaction with the rest of the genome.
Bioethical issues arising from the Human Genome Project
This program aims to explore how knowledge of the genome can interact with a variety of philosophical, theological, and ethical perspectives, and to examine how genetic information affects racial, ethnic, and socioeconomic factors.
It is considered that, although the human genome is regarded as the “heritage of humanity”, individual persons must be protected and the intended use of the information in the applied field must be taken into account. The current priorities of the ELSI program fall into four broad categories that affect Medicine, Law, Public Order, and Society. A quarter of a century after the draft human genome, the mission of the ELSI program has added other objectives such as the exploration of the human microbiome, genealogy and genetic ancestry studies, the consequences of gene editing, etc.
The substantial body of knowledge derived from the HGP has led to key statements and publications by international institutions and organizations, aimed at regulating its applications and highlighting ethical implications. The two main documents are the UNESCO “Universal Declaration on the Human Genome and Human Rights”, adopted in Paris on 11 November 1997, and the UNESCO “International Declaration on Human Genetic Data”, adopted in Paris on 16 October 2003.
The common element for reflection in these statements is the value and dignity of human life. Thus, article 1 of the Universal Declaration states that: “The human genome underlies the fundamental unity of all members of the human family, as well as the recognition of their inherent dignity and diversity. In a symbolic sense, it is the heritage of humanity”, while Article 10 says that: “No research or research applications concerning the human genome, in particular in the fields of biology, genetics and medicine, should prevail over respect for the human rights, fundamental freedoms and human dignity of individuals or, where applicable, of groups of people”.
The question we can ask ourselves is whether these good intentions are being fulfilled. With full knowledge of the facts, we can be skeptical that this is the case in controversial areas such as the application of genetic diagnosis for eugenic purposes, as is the case with preimplantation genetic diagnosis for the selection and/or elimination of embryos, or prenatal diagnosis in order to find out if the fetus has potential alterations due to genetic defects in its DNA or chromosomal makeup. The intentions behind these tests are not difficult to guess, since performing pharmacological or surgical correction before birth or in utero is impossible in most cases, which has facilitated their use for carrying out “eugenic”, “embryopathic” or “euthanasic” abortions.
Genetic diagnosis has a more positive aspect as a source of information for the practice of “genetic counseling”, which is defined in the Spanish Biomedical Research Law, as “the procedure aimed at informing a person about the possible consequences for him or his descent about the results of a genetic analysis or screening, its advantages and risks and, where appropriate, counselling on the possible alternatives derived from the analysis. It shall take place before as well as after a genetic test or screening and even in the absence of both”. The Spanish Bioethics Committee Spain gave a detailed report on how to carry out prenatal genetic counseling, published in 2015.
The provisions of Article 5 of the Universal Declaration are also important: “Research, treatment or diagnosis affecting an individual’s genome shall be undertaken only after rigorous and prior assessment of the risks and benefits pertaining thereto … The right of each individual to decide whether or not to be informed of the results of genetic examination and the resulting consequences should be respected”.
Article 4 of the subsequent International Declaration states that: “Due consideration should be given to the sensitivity of human genetic data and an appropriate level of protection for these data and biological samples should be established”.
While an individual’s data is considered a private matter, it is also true that it can be of great importance to their relatives and genetically related persons. Therefore, when presented with a genetic diagnosis indicating that an adult is a carrier of a disease-causing gene, conflicts of interest between the right to privacy, the right to not know and the right of third parties to access medical data must be considered.
Another ethical aspect in relation to genetic diagnosis in adults arises in relation to the medical examination prior to signing an employment contract or for the establishment of an insurance policy. Presenting a medical record about past or current diseases is not the same as requesting a DNA analysis that could reveal the risk of contracting a disease in the future. This is the true power of genetic diagnosis, which is not absolute, either in the precision of the time of onset of the disease or in the prognosis of its severity.
Nicolás Jouve
Professor Emeritus of Genetics at the University of Alcalá
Member of the Bioethics Observatory of the Catholic University of Valencia
References: